Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis (Q28476120)

6

0 references

Christian Lienhardt

8

object named as

Christian Lienhardt

0 references

author name string

Andrea Benedetti

2

0 references

Anita Paydar

3

0 references

Ian Martin

4

0 references

Sarah Royce

5

0 references

Andrew Vernon

7

0 references

William Burman

Creative Commons CC0 License

9

0 references

language of work or name

English

0 references

publication date

September 2009

0 references

1 September 2009

4 references

23 March 2019

22 June 2019

17 September 2019

13 November 2019

4 references

23 March 2019

22 June 2019

17 September 2019

13 November 2019

6

0 references

issue

9

0 references

page(s)

e1000146

0 references

copyright license

4 references

23 March 2019

22 June 2019

17 September 2019

on focus list of Wikimedia project

13 November 2019

copyright status

public domain

0 references

ScienceSource

0 references

cites work

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Effectiveness of standard short-course chemotherapy for treating tuberculosis and the impact of drug resistance on its outcome

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Indexation of psychiatric journals from low- and middle-income countries: a survey and a case study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

A bibliometric analysis of tuberculosis research indexed in PubMed, 1997-2006.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Long term efficacy of DOTS regimens for tuberculosis: systematic review.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Treatment of multidrug-resistant tuberculosis: evidence and controversies.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Controlling the risk of spurious findings from meta-regression.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Investigating causes of heterogeneity in systematic reviews

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Four-month chemotherapy in the treatment of smear-negative pulmonary tuberculosis: results at 30 to 60 months.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Fully intermittent dosing with drugs for tuberculosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Regimens of less than six months for treating tuberculosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Tuberculosis. Cause of death in antibiotic era.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Comparison of a conventional and an initial 2-month intensive drug regimen for treating pulmonary tuberculosis in Swaziland.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

[Controlled study comparing 3 daily chemotherapy regimens for six months in pulmonary tuberculosis in routine practice in Algiers. Results at 30 months]

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Short course chemotherapy for pulmonary tuberculosis. A randomised controlled trial of a six month versus a nine month oral regimen.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Treatment of pulmonary tuberculosis with short course chemotherapy in south India--5-year follow up.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

[A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment]

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

The binomial distribution of meta-analysis was preferred to model within-study variability.

2 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000146

Explaining heterogeneity in meta-analysis: a comparison of methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000146

Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000146

Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000146

Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clini

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000146

Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000146

Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000146

A survey of deaths in Hong Kong attributed to tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000146

Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Revised international definitions in tuberculosis control.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Drug-resistant pulmonary tuberculosis in a cohort of southern African goldminers with a high prevalence of HIV infection.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Tuberculosis treated with rifampicin, ethambutol and isoniazid: Danish tuberculosis trial 1972-1974.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Deaths occurring in newly notified patients with pulmonary tuberculosis in England and Wales

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736385

Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report of 4th study. East African and British Medical Research Councils

27 November 2018

1 reference

12 December 2020

A controlled trial of a 2-month, 3-month, and 12-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: the results at 30 months. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council

1 reference

12 December 2020

Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Tanzania/British Medical Research Council Study

1 reference

12 December 2020

A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association

1 reference

12 December 2020

Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group

1 reference

12 December 2020

Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment

1 reference

12 December 2020

Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months

1 reference

12 December 2020

Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council

1 reference

12 December 2020

[Controlled clinical trial of a 3-month regimen and 2 5-month regimens in the treatment of pulmonary tuberculosis. 2d study of the short-term treatment administered in Madras]

1 reference

12 December 2020

Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report

1 reference

12 December 2020

Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin

1 reference

12 December 2020

Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore

1 reference

12 December 2020

Rifampin in original treatment of pulmonary tuberculosis. A United States Public Health Service cooperative therapy trial

1 reference

12 December 2020

Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils

1 reference

12 December 2020

Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment

1 reference

12 December 2020

Six-months isoniazid-rifampin therapy for pulmonary tuberculosis. Report of a United States Public Health Service Cooperative Trial

1 reference

12 December 2020

Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India

1 reference

12 December 2020

Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis

1 reference

12 December 2020

Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report

1 reference

12 December 2020

A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Hong Kong Chest Service/tuberculosis Research Centre, Madras/British Medical Research Council

1 reference

12 December 2020

A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore

1 reference

12 December 2020

Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council

1 reference

12 December 2020

Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study

1 reference

12 December 2020

Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council Study

1 reference

12 December 2020

Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month

1 reference

12 December 2020

Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months

1 reference

12 December 2020

Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council

1 reference

12 December 2020

Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council

1 reference

12 December 2020

Importance of rifampicin in combined daily/intermittent chemotherapy for tuberculosis

1 reference

12 December 2020

Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study

1 reference

12 December 2020

Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis

1 reference

12 December 2020

Controlled clinical trial of levamisole in short-course chemotherapy for pulmonary tuberculosis. A Kenyan/Zambian/British Medical Research Council Collaborative Study

1 reference

12 December 2020

Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. The results up to 30 months

1 reference

12 December 2020

Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council

1 reference

12 December 2020

Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. A report from the British Medical Research Council

1 reference

12 December 2020

Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council

1 reference

12 December 2020

Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study

1 reference

12 December 2020

A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council

1 reference

12 December 2020

A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months

1 reference

12 December 2020

Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian working group/British Medical Research Council cooperative study

1 reference

12 December 2020

Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association

1 reference

12 December 2020

Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report

1 reference

12 December 2020

Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis

1 reference

12 December 2020

A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association

1 reference

12 December 2020

Delay in diagnosis among hospitalized patients with active tuberculosis--predictors and outcomes

1 reference

12 December 2020

Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association

1 reference

12 December 2020

Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: The results up to 24 months

1 reference

12 December 2020

[Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose]

1 reference

12 December 2020

Short-course chemotherapy for pulmonary tuberculosis under routine programme conditions: a comparison of regimens of 28 and 36 weeks duration in Algeria. Algerian Working Group/British Medical Research Council Cooperative Study

1 reference

12 December 2020

10.1371/JOURNAL.PMED.1000146

Identifiers

DOI

1 reference

1 reference

1 reference

PubMed publication ID

19753109

1 reference